IMDX

Insight Molecular Diagnostics Inc. NASDAQ

Healthcare ·Biotechnology ·US · imdxinc.com

$5.23

Mkt Cap $140.4M

52w Low $2.33 46.9% of range 52w High $8.51

50d MA $4.27 200d MA $4.71

P/E (TTM) -2.5x

EV/EBITDA -7.8x

P/B —

Debt/Equity -0.1x

ROE 159.6%

P/FCF -9.0x

RSI (14) —

ATR (14) —

Beta 1.53

50d MA $4.27

200d MA $4.71

Avg Volume 222.4K

About

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 26, 2026	AMC	-0.24	-0.27	-13.7%	4.11	+1.5%	-13.4%	-38.0%	-20.2%	-16.3%	-8.5%	-6.6%	—
Nov 10, 2025	AMC	-0.24	-0.34	-41.7%	6.80	-2.2%	+10.7%	+24.7%	+15.4%	+8.8%	-1.5%	-25.1%	—
Aug 11, 2025	AMC	-0.23	-0.30	-30.4%	2.61	-6.1%	-3.8%	-6.1%	-8.0%	-8.0%	+2.3%	+14.9%	—
May 12, 2025	AMC	-0.24	-0.26	-8.3%	2.81	+0.4%	-1.4%	-7.5%	-0.7%	-0.7%	-0.4%	-6.0%	—
Mar 24, 2025	AMC	-0.43	0.48	+211.6%	3.33	+9.3%	-8.7%	-4.5%	-3.3%	-3.6%	-8.1%	-11.4%	—
Nov 12, 2024	AMC	-0.44	-0.98	-122.7%	3.00	+0.0%	-2.0%	-6.7%	-13.0%	-12.3%	-15.0%	-20.3%	—
Aug 8, 2024	AMC	-0.56	-0.36	+35.7%	3.08	-3.9%	+1.3%	-3.9%	-1.0%	-1.9%	-4.2%	+3.6%	—
May 15, 2024	AMC	-0.67	-1.13	-68.7%	2.95	-8.5%	+4.1%	-0.7%	-6.4%	-4.4%	-1.4%	-6.4%	—
Mar 29, 2024	AMC	-1.57	-1.94	-23.3%	—	—	—	—	—	—	—	—	—
Nov 9, 2023	AMC	-1.52	-0.57	+62.5%	2.70	-2.9%	+3.0%	+2.2%	+23.8%	+46.8%	+51.2%	+11.6%	—
Aug 10, 2023	AMC	-2.60	-1.07	+58.8%	3.51	+0.0%	-0.6%	-2.6%	-4.8%	-4.8%	-4.0%	-5.4%	—
May 11, 2023	AMC	-2.40	-0.80	+66.7%	5.46	+5.1%	-7.7%	-2.6%	-3.3%	-2.6%	-6.6%	-21.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Feb 17	Lake Street	Maintains	Buy → Buy	—	$5.57	$5.58	+0.2%	-3.2%	-4.5%	-2.5%	-1.4%	+2.2%
Nov 11	Needham	Maintains	Buy → Buy	—	$6.80	$6.65	-2.2%	+10.7%	+24.7%	+15.4%	+8.8%	-1.5%
Aug 18	Needham	Maintains	Buy → Buy	—	$2.40	$2.51	+4.6%	+11.2%	+8.3%	+4.2%	+3.3%	+7.9%
May 21	Lake Street	Maintains	Buy → Buy	—	$2.94	$2.83	-3.7%	+4.4%	+17.0%	+14.6%	+10.5%	+13.3%
May 13	Needham	Maintains	Buy → Buy	—	$2.81	$2.82	+0.4%	-1.4%	-7.5%	-0.7%	-0.7%	-0.4%
Apr 8	Needham	Maintains	Buy → Buy	—	$2.84	$3.18	+12.0%	-3.2%	+3.9%	+2.1%	-2.1%	+0.4%
Mar 26	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$3.04	$3.03	-0.3%	+4.6%	+5.9%	+5.6%	+0.7%	-1.3%
Mar 25	Stephens & Co.	Maintains	Equal Weight → Equal Weight	—	$3.33	$3.64	+9.3%	-8.7%	-4.5%	-3.3%	-3.6%	-8.1%
Mar 25	Needham	Maintains	Buy → Buy	—	$3.33	$3.64	+9.3%	-8.7%	-4.5%	-3.3%	-3.6%	-8.1%
Aug 23	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$3.52	$3.39	-3.7%	+4.3%	-3.4%	-5.7%	-2.0%	+0.9%
Aug 14	Piper Sandler	Maintains	Neutral → Neutral	—	$3.49	$3.37	-3.4%	-2.0%	-4.3%	-4.3%	-3.4%	+4.9%
Aug 9	Needham	Maintains	Buy → Buy	—	$3.58	$3.51	-2.0%	-2.0%	-2.0%	-2.5%	-4.5%	-6.7%
Apr 4	Needham	Maintains	Buy → Buy	—	$6.36	$6.42	+0.9%	-8.8%	-15.1%	-2.5%	+10.1%	+6.0%
Dec 1	Lake Street	Downgrade	Buy → Hold	—	$9.40	$9.40	+0.0%	+1.1%	+6.2%	+2.1%	+2.1%	-1.3%
Nov 18	Piper Sandler	Downgrade	Overweight → Neutral	—	$8.52	$8.52	+0.0%	+3.3%	-0.7%	+5.6%	+11.7%	+10.3%
Nov 14	Piper Sandler	Maintains	Overweight → Overweight	—	$9.40	$9.60	+2.1%	-12.8%	-13.2%	-17.7%	-9.4%	-6.4%
Nov 11	Needham	Maintains	Buy → Buy	—	$12.00	$13.20	+10.0%	-21.7%	-31.7%	-32.0%	-35.5%	-29.0%
Aug 17	Piper Sandler	Maintains	Overweight → Overweight	—	$18.32	$18.82	+2.7%	-4.6%	+0.4%	-1.2%	-2.8%	-3.9%
Aug 11	Lake Street	Maintains	Buy → Buy	—	$19.02	$19.00	-0.1%	+2.8%	-0.9%	+2.0%	-3.7%	-8.1%
Aug 11	Needham	Maintains	Buy → Buy	—	$19.02	$19.00	-0.1%	+2.8%	-0.9%	+2.0%	-3.7%	-8.1%
May 24	Stephens & Co.	Downgrade	Overweight → Equal Weight	—	$21.60	$20.60	-4.6%	-8.9%	-9.3%	-5.6%	-3.7%	+0.0%
May 16	Piper Sandler	Maintains	Overweight → Overweight	—	$22.60	$22.60	+0.0%	+2.7%	+3.5%	+0.9%	-0.9%	-1.8%
May 12	Needham	Maintains	Buy → Buy	—	$22.60	$22.20	-1.8%	-3.5%	+0.0%	+2.7%	+3.5%	+0.9%
Mar 18	Piper Sandler	Maintains	Overweight → Overweight	—	$26.80	$27.60	+3.0%	+19.4%	+5.2%	+5.2%	+2.2%	+3.7%
Mar 14	KeyBanc Capital Markets	Downgrade	Overweight → Sector Weight	—	$25.80	$25.20	-2.3%	-10.9%	-10.9%	-7.0%	+3.9%	+24.0%
Mar 13	KeyBanc Capital Markets	Downgrade	Overweight → Equal Weight	—	—	—	—	—	—	—	—	—
Mar 11	Needham	Maintains	Buy → Buy	—	$28.00	$30.00	+7.1%	-7.9%	-17.9%	-17.9%	-14.3%	-4.3%
Mar 11	Lake Street	Maintains	Buy → Buy	—	$28.00	$30.00	+7.1%	-7.9%	-17.9%	-17.9%	-14.3%	-4.3%
Jan 7	Stephens & Co.	Maintains	Overweight → Overweight	—	$41.20	$41.60	+1.0%	+0.0%	-1.5%	-5.3%	-5.3%	-9.2%
Dec 16	Needham	Maintains	Buy → Buy	—	$45.80	$45.80	+0.0%	-3.9%	-5.7%	-2.2%	+0.9%	+2.2%
Nov 10	Needham	Maintains	Buy → Buy	—	$71.60	$69.00	-3.6%	-6.4%	-5.0%	-12.8%	-16.5%	-16.2%
Dec 16	Piper Sandler	Upgrade	Neutral → Overweight	—	$50.60	$50.40	-0.4%	+4.0%	-3.6%	-2.8%	+0.0%	+0.8%
Nov 30	BTIG	Maintains	Buy → Buy	—	$35.80	$38.20	+6.7%	+7.8%	+7.8%	+9.5%	+8.9%	+10.6%
Nov 13	Needham	Maintains	Buy → Buy	—	$33.60	$34.00	+1.2%	+3.6%	+6.5%	+6.5%	+4.2%	+6.5%
Nov 10	KeyBanc	Maintains	Overweight → Overweight	—	$30.40	$32.80	+7.9%	+11.8%	+15.1%	+10.5%	+14.5%	+17.8%
Jul 30	Benchmark	Maintains	Speculative Buy → Speculative Buy	—	$27.40	$26.20	-4.4%	+6.6%	-1.5%	+16.1%	+38.0%	+29.9%
Jul 29	Benchmark	Maintains	Speculative Buy → Buy	—	$28.60	$29.00	+1.4%	-4.2%	+2.1%	-5.6%	+11.2%	+32.2%
Jul 1	Needham	Maintains	Buy → Buy	—	$38.20	$35.20	-7.9%	-12.0%	-18.8%	-30.4%	-34.6%	-33.0%
Jun 30	Chardan Capital	Downgrade	Buy → Neutral	—	$64.60	$32.00	-50.5%	-40.9%	-48.0%	-52.0%	-58.8%	-61.3%
Jun 2	Needham	Maintains	Buy → Buy	—	$54.60	$57.20	+4.8%	-2.9%	-2.9%	-5.1%	-4.0%	-8.8%
Feb 13	PiperJaffray	Maintains	Overweight → Overweight	—	$76.80	$83.20	+8.3%	+0.5%	+0.3%	-1.0%	-0.8%	-0.5%
Feb 23	Chardan Capital	Maintains	Buy → Buy	—	$101.00	$101.00	+0.0%	-1.4%	+2.0%	+11.9%	+11.9%	+12.9%
May 13	Benchmark	Maintains	Speculative Buy → Buy	—	$86.60	$86.00	-0.7%	-7.2%	-10.4%	-9.7%	-6.0%	-5.3%
Mar 24	Lake Street	Maintains	Buy → Buy	—	$101.20	$100.00	-1.2%	+0.2%	+4.0%	-0.2%	-6.5%	-8.9%
Mar 15	Janney Capital	Maintains	Buy → Buy	—	$124.20	$125.00	+0.6%	-6.3%	-2.6%	-8.5%	-11.3%	-13.2%

Recent Filings

8-K

Unknown — 8-K Filing

IMDX submitted its flagship GraftAssureDx test for FDA review, potentially opening a significant revenue stream in kidney transplant rejection diagnostics if approved.

Mar 26

8-K · 1.01 !! High

Insight Molecular Diagnostics Inc. -- 8-K 1.01: Material Agreement

Insight Molecular Diagnostics partnered with Quest Diagnostics through a specimen collection agreement, potentially expanding IMDX's diagnostic reach and revenue streams via Quest's extensive laboratory network.

Feb 26

8-K · 8.01 !! High

Insight Molecular Diagnostics Inc. -- 8-K 8.01: Material Event / Announcement

IMDX announced a material event that likely signals a significant business development, partnership, or operational change that could substantially impact revenue, profitability, or market position.

Feb 12

8-K · 7.01 ! Medium

Insight Molecular Diagnostics Inc. -- 8-K 7.01: Regulation FD Disclosure

Insight Molecular Diagnostics disclosed regulatory information via 8-K filing with no obligation to update materials, indicating a one-time disclosure event rather than ongoing commitment to investors.

Feb 11

Data updated apr 25, 2026 3:16pm · Source: massive.com